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Objectives Our purpose was to evaluate the long-term use of sirolimus-eluting stents (SES) and bare-metal stents (BMS) in
patients with complex coronary artery lesions.
Background Although the use of SES has proved to be effective in patients with simple coronary artery lesions, there are lim-
ited data of the long-term outcome of patients with complex coronary artery lesions.
Methods We randomly assigned 322 patients with total coronary occlusions or lesions located in bifurcations, ostial, or
angulated segments of the coronary arteries to have SES or BMS implanted.
Results At 3 years, major adverse cardiac events had occurred in 20 patients (12%) in the SES group and in 59 patients
(38%) in the BMS group (p  0.001). Four versus 2 patients suffered a cardiac death (p  NS), and 5 versus 1
died of a noncardiac disease (p  NS) in the SES versus the BMS group. Six patients in the SES group versus 15
patients in the BMS group suffered a myocardial infarction (p  0.05) during the 3-year observation period, and
target lesion revascularization was performed in 8 patients (4.9%) versus 53 patients (33.8%), respectively (p 
0.001); of these, 4 in the SES versus 7 in the BMS group were performed between 1 and 3 years after the index
treatment (p  NS). According to revised definitions, stent thrombosis occurred in 5 patients (3.1%) in the SES
group and in 7 patients (4.4%) in the BMS group (p  NS); very late stent thrombosis was observed in 4 versus
1 patient.
Conclusions A continued benefit was observed up to 3 years after implantation of SES in patients with complex coronary ar-
tery lesions. The rate of late adverse events was similar in the 2 groups, and stent thromboses occurred rarely
after 1 year. (Sirolimus Eluting Stents in Complex Coronary Lesions [SCANDSTENT]; NCT00151658) (J Am Coll
Cardiol 2008;51:2011–6) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.056f
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Nrug-eluting stents (DES) reduce the rate of both angio-
raphic and clinical restenosis in simple coronary artery
esions (1–3), whereas the experience of their use in complex
esions is limited (4,5). Patients with total coronary occlu-
ions and lesions located in bifurcations, ostial regions, or
ngulations have been consequently excluded from most
revious trials, and recommendations for DES have there-
rom *Rigshospitalet, Copenhagen; †Skejby Sygehus, Skejby; ‡Odense Universitet-
hospital, Odense; §Gentofte Hospital, Gentofte; and the ¶Roskilde Hospital,
oskilde, Denmark. The authors of this study have received unrestricted grants from
ordis/Johnson & Johnson, Abbott, Medtronic, and Boston Scientific.s
Manuscript received November 8, 2007; revised manuscript received January 4,
008, accepted January 7, 2008.ore been limited to on-label use in rather simple coronary
rtery lesions (6).
See page 2025
Late adverse events recently have been indicated to occur
ore frequently in patients who have DES implanted
ompared with those who have received bare-metal stents
BMS) (7–10). Long-term follow up of different categories
f patients and lesions is therefore warranted. The authors
f the SCANDSTENT (Stenting Coronary Arteries in
on-Stress/Benestent Disease) trial reported improvedhort-term clinical and angiographic outcomes after im-
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3-Year Results of the SCANDSTENT Trial May 27, 2008:2011–6plantation of 1 or more sirolimus-
eluting stents (SES) compared
with BMS in patients with com-
plex coronary artery lesions (11),
and a recent report focused upon
the short-term clinical course after
changing from dual- to mono-
antiplatelet therapy (12). The
present study was undertaken to
reveal the long-term clinical out-
come after SES versus BMS im-
plantation in SCANDSTENT
patients with complex coronary le-
sions, with special attention given
to events occurring 1 to 3 years
fter the index treatment, during which a vast majority of the
atients were on antithrombotic monotherapy.
ethods
tudy design. The trial was conducted at 4 Danish centers
ith invasive cardiology. The objective of this study was to
ompare the 3-year clinical outcome in patients participat-
ng in the SCANDSTENT trial who had been randomized
o have either an SES or BMS implanted in their complex
oronary artery lesions. Criteria for inclusion and exclusion
f patients have been described elsewhere (11). In brief,
atients with symptomatic coronary artery disease and at
east 1 complex lesion in a native coronary vessel were
ncluded provided they had at least 1 total or subtotal
cclusion, a bifurcation lesion with a side branch of signif-
cant size, a lesion located in an ostium, or a lesion located
n a tortuous segment of a coronary artery. No restrictions
ere applied with regard to vessel size or lesion length.
xclusion criteria were myocardial infarction (MI) 3 days
efore the procedure or lesions in unprotected left main
tems or in bypass grafts. The protocol was approved by the
ocal ethics committees, and all patients consented to
articipate in writing.
tudy procedures. After pre-dilation of the lesions, pa-
ients were randomized by computerized assignment strat-
fied with regard to gender and the presence of diabetes.
he Bx Velocity balloon-expandable stent (Cordis/Johnson
Johnson, Miami Lakes, Florida) or the Cypher balloon-
xpandable stent (Cordis/Johnson & Johnson) was im-
lanted in the lesions under high pressure (12 atms). Long
esions and dissections were treated with supplementary
tents of the same type as the one(s) implanted in the index
esion. Bifurcations were treated as previously described
13). Stenting of the side branch in bifurcations was
erformed at the discretion of the operator attempting to
eep the side branch open. Heparin was administered to
aintain the activated clotting time at 250 s during the
rocedure, and all patients were treated with clopidogrel for
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stents
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationt least 1 year after the procedure and aspirin indefinitely. clycoprotein receptor antagonists were used at the discre-
ion of the operator. In patients who underwent percutane-
us coronary intervention (PCI) again or a nontarget lesion
CI in the follow-up period, clopidogrel was continued for
2 months after the last stent implantation.
ollow-up. Reangiography was performed in connection
ith recurrent symptoms and in any case at 6 months, and
ll patients were followed clinically for 3 years after stent
mplantation. In case of rehospitalization of the patients, the
ourse was carefully monitored by the study coordinator to
dentify any target vessel involvement.
tudy end points and definitions. The primary end point
f the original trial was an angiographic reduction in the
inimal lumen diameter of the target lesion (11). The focus
f this study was the occurrence of major adverse cardiac
vents (MACE) and stent thrombosis within 3 years after
tent implantation. Major adverse cardiac events were de-
ned as death from any cause, MI, and target lesion
evascularization (TLR). An MI was defined as the devel-
pment of new Q waves lasting 0.4 s in at least 2
ontiguous leads and/or an increase in blood concentrations
f creatine kinase (total) 2 times the upper normal limit
ith a concomitant increase in creatine kinase-myocardial
and blood concentration. Target lesion revascularization
as defined as repeat revascularization, PCI within 5 mm
roximally or distally to the stent or coronary bypass surgery
f the target vessel, including side branches of bifurcations
n the presence of myocardial ischemia, or a 70% target
esion diameter stenosis (regardless of symptoms). A target
essel revascularization included both TLR and repeat
evascularization in the target vessel remote of the target
esion. A stent thrombosis was considered definite in the
ase of an acute coronary syndrome with angiographically
isible signs of a contrast filling defect or occlusion of the
arget lesion according to definitions suggested by the
cademic Research Consortium (10). Probable stent
hromboses included any unexplained death within 30 days
r a target vessel MI (without angiographic documenta-
ion). A possible stent thrombosis was present in case of any
nexplained death later than 30 days after stent implanta-
ion. Early stent thrombosis occurred within 1 month, late
tent thrombosis from 1 to 12 months, and very late stent
hrombosis after 1 year.
tatistical analysis. The original study was powered to
etect a significant increase in the target lesion minimal
umen diameter in the SES compared with the BMS group.
n addition, the inclusion of 300 patients was sufficient to
etect a 40% reduction in MACE in the 2 groups with a
ower of 80% and a type 1 error of 0.05. Differences in
ategorical variables were analyzed with the use of the
isher exact test, and continuous variables were analyzed
ith the Student t test for unpaired samples. The Kaplan-
eier method was used to create survival estimates, and the
og-rank test was used to test differences in these estimates.
nivariate odds ratio and 95% confidence intervals forategorical values were calculated using 2  2 tables. All
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May 27, 2008:2011–6 3-Year Results of the SCANDSTENT Trialnalyses were performed with the use of the SPSS statistical
ackage version 15 (SPSS Inc., Chicago, Illinois). All p
alues were 2-sided.
esults
f the 322 patients included in the trial, 3 patients were
xcluded from the analyses because of technical problems as
reviously described (11). All events, even those occurring
fter TLR, were imputed to the original treatment group,
ccording to the intention-to-treat principle.
ACE. The patients were well matched with regard to
linical characteristics (Table 1). Within 3 years, 9 patients
n the SES group and 3 patients in the BMS group died
p  0.06), of which 4 were cardiac deaths (1 probable and
possible stent thromboses) in the SES group versus 2
ardiac deaths (1 definite stent thrombosis and 1 due to
rogressive heart failure) in the BMS group. Five deaths in
he SES group were noncardiac (3 the result of cancer of the
iver, prostate, and colon; 1 the result of pneumonia; and 1
he result of rupture of an aortic aneurysm) versus 1 in the
MS group (the result of pneumonia).
During the 3-year follow-up period, MI was observed in
patients in the SES group versus 15 patients in the BMS
roup (p 0.04). In 6 cases in the BMS group versus 1 case
n the SES group, the MI was related to a stent thrombosis
definite or probable).
Target lesion revascularization was performed in 8 (4.9%)
f the patients with a SES versus 53 (33.8%) of those with
BMS (p  0.001) (Fig. 1). Restenosis in the SES group
as treated with balloon angioplasty in 4 cases, with a new
rug-eluting stent in 3 cases, and with coronary artery
ypass surgery in 1 case. Restenosis in the BMS group was
reated with a drug-eluting stent in 36 cases (SES in 83%),
ith balloon angioplasty in 10 cases, and with coronary
rtery bypass surgery in 2 cases, whereas 1 patient received
nother BMS and 1 patient no treatment. Four cases of
emographic Data of the Patients
Table 1 Demographic Data of the Patients
SES
(n  163)
BMS
(n 159) p Value
Age (yrs) 62.9 (9.2) 62.5 (9.4) 0.94
Male gender (%) 74 79 0.30
Diabetes (%) 18 18 0.90
Hypertension (%) 46 38 0.21
Hyperlipidemia (%) 81 84 0.46
Previous myocardial
infarction (%)
54 50 0.58
Unstable angina (%) 25 26 0.70
Multivessel disease (%) 43 45 0.29
Coronary artery,
LAD/CX/RCA (%)
45/25/30 53/23/24 0.31
Lesion length (mm) 18.8 (13.0) 17.2 (11.1) 0.43
umbers are mean values with SD in parentheses.
BMS  bare-metal stent; CX  circumflex artery; LAD  left anterior descending artery; RCA 
ight coronary artery; SES  sirolimus-eluting stent.LR in the SES group and 7 in the BMS group wereerformed between 1 and 3 years after the index treatment.
f 29 patients who suffered a late event, 3 of 14 patients in
he SES group (21%) versus 10 of 15 patients in the BMS
roup (67%) had had a previous event (p  0.03).
During the 3-year period after stent implantation,
ACE occurred in 20 patients (12.3%) in the SES group
nd in 59 patients (37.6%) in the BMS group (p  0.001);
herefore, the initial clinical improvement of SES compared
ith BMS implantation was continued during the whole
bservation period (Fig. 2).
ubgroup analysis. The results of the subgroup analysis
emonstrated a long-term benefit of SES versus BMS
mplantation in all subsets of patients (Fig. 3). None of the
Figure 1 MACE Within 3 Years After Stent Implantation
Frequency of major adverse cardiac events (MACE) (i.e., death, myocardial
infarction, and target lesion revascularization [TLR]), occurring 3 years after
implantation of sirolimus-eluting stents (SES) and bare-metal stents (BMS).
TVR  target vessel revascularization.
Figure 2 Kaplan-Meier Estimates of Survival Free From MACE
Abbreviations as in Figure 1.
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3-Year Results of the SCANDSTENT Trial May 27, 2008:2011–6iabetic patients in the SES group had TLR performed
uring the 3-year period, and only 3 diabetics (10.3%)
uffered MACE. Although some of the subgroups of lesion
ypes were too small to show a significant difference, the
ame trend toward a lower rate of MACE in the SES versus
he BMS group was observed in all types of complex lesions
Table 2).
tent thrombosis. According to revised definitions, stent
hrombosis occurred in 12 patients totally: 7 were classified
s definite, 2 as probable, and 3 as possible stent thromboses
Table 3). At the time of stent thrombosis, 4 of 5 patients
n the SES group were on single antiplatelet therapy,
hereas 6 of 7 patients in the BMS group were on dual
ntiplatelet therapy. Of the definite stent thromboses, 6
ccurred in a BMS, and very late stent thrombosis occurred
n 4 patients (2.5%) in the SES group and 1 (0.6%) in the
MS group. With the exception of 1 patient who developed
lopidogrel allergy, all patients who suffered a definite or a
robable stent thrombosis were on clopidogrel treatment at
he time of stent thrombosis.
MACE in Different Types of Lesions
Table 2 MACE in Different Types of Lesions
SES (n  1
Occlusions (n  115), n (%) 4 (6.8)
Bifurcations (n  107), n (%) 11 (19.3
Ostial lesions (n  72), n (%) 4 (11.4
Angulation (n  25), n (%) 1 (8.3)
Total 20 (12.3
Figure 3 Subgroup Analysis for the 3-Year Rate of MACE
Odds ratios for the occurrence of MACE in the SES and BMS groups. CI  con-
fidence intervals; CX  circumflex artery; LAD  left anterior descending artery;
RCA  right coronary artery; other abbreviations as in Figure 1.Abbreviations as in Table 1.iscussion
n this randomized study involving patients with complex
oronary artery lesions, implantation of SES resulted in an
mproved clinical outcome after 3 years in comparison with
hat associated with the implantation of BMS. Implantation
f SES markedly reduced the frequency of both TLR and
ACE compared with BMS in our patients, and even from
to 3 years, both the occurrence of MI and TLR were
ignificantly lower in the SES group. Thus, the clinical
enefit of SES implantation reported after 6 months, with
egard to reducing neointimal growth in the stent and
hereby lowering the need for repeat revascularization,
ontinued beyond the point when more than 95% of the
atients had discontinued their dual antiplatelet therapy,
ithout increasing the risk of late adverse events. These
ndings contribute to closing some of the gaps between
pproved indications for the use of DES and their real-
orld applications (14).
eath and MI. There seemed to be a trend toward an
ncrease in death from any cause in the SES group com-
ared with the BMS group in a 3-year follow-up of the
AVEL (Randomized Comparison of a Sirolimus-Eluting
tent With a Standard Stent for Coronary Revasculariza-
ion) trial that included patients with simple coronary artery
esions, mainly because of a slight overweighting of noncar-
iac deaths occurring in the SES group (15). Although the
resent study was not powered to address hard end points,
similar unexplained trend toward greater all-cause mor-
ality in the SES group urges a continued close monitoring
f the clinical course of these patients. On the other hand,
arge-scale pooled analyses of randomized trials that com-
ared long-term outcomes after implantation of drug-
luting stents versus BMS in a large variety of coronary
rtery lesions did not reveal any difference in either cardiac
r noncardiac mortality (16–18). In addition, it is hard to
xplain a connection between the stent type and 3 deaths
ue to cancer, 1 due to pneumonia, and 1 due to aortic
upture in the SES group versus 1 death due to pneumonia
n the BMS group.
We found a greater rate of MI in the BMS group that at
east, to some extent, can be explained by an excess rate of
efinite stent thrombosis in the target lesion. On the other
and, we are unable to rule out that a MI might have
ccurred in connection with some of the cases of sudden
eath in the SES group. That MI occurs at similar frequen-
BMS (n  157) p Value
23 (41.1) 0.001
19 (36.5) 0.054
14 (36.8) 0.014
3 (23.1) 0.59
59 (37.1) 0.00162)
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May 27, 2008:2011–6 3-Year Results of the SCANDSTENT Trialies in patients treated with drug-eluting and BMS has been
emonstrated in large-scale pooled analyses of the long-
erm outcome in patients included in randomized trials
16–20).
ntiplatelet therapy. Only few of the previous trials have
ocused on patients with lesions such as bifurcations, total
cclusions, and ostial and angulated lesions (21,22); there-
ore, long-term experience is limited to patients with rela-
ively simple coronary lesions (15,23,24). A comparison of
ur data with the 3-year clinical outcome of patients with
ery simple coronary lesions reveals a similar MACE rate in
oth patients treated with SES and BMS (15). On the other
and, it must be taken into consideration that all of our
atients were treated with clopidogrel for 12 months after
he index stent implantation as opposed to only 2 months in
he RAVEL trial. In addition, as the result of a greater rate
f multivessel disease, 10% of the SCANDSTENT patients
ere treated with PCI, including stent implantation, in a
ontarget lesion after the first 12-month period and thus
eceived dual antiplatelet therapy for an even longer period.
tent thrombosis. Implantation of DES not only decreases
eointimal hyperplasia but may induce pathological changes
nvolving a process of delayed healing of the coronary artery
all not observed in association with the implantation of
MS (25). It was not until recently, however, that reports
aised concerns about the use of DES because of a risk of
ate stent thrombosis and MI, especially in patients with
omplex disease or complex coronary artery lesions (7,9,26).
ur patients all had complex coronary lesions and, thus,
heir clinical outcome contributes to the long-term experi-
nce with DES in patients with “off-label” lesions. Our
tudy did not reveal any difference in the occurrence of stent
hrombosis in the 2 groups but was, on the other hand, not
owered to detect such a difference.
ate events and events after TLR. Almost 10% of the
CANDSTENT patients suffered an event between 1 and
years. In the SES group, a late event was considerably
ore likely to be a first event, whereas late events were
econd events in a majority of the BMS patients. Thus,
revious events do not protect against events occurring later
n the clinical course after BMS implantation in complex
esions.
As stressed by Mauri et al. (19), events occurring after
LR were previously censored according to protocol de-
tent Thrombosis
Table 3 Stent Thrombosis
SES (n  162)
Definite (%) Probable (%) Possi
Early 0 1 (0.6)
Late 0 0
Very late 1 (0.6) 0 3 (
Total 1 (0.6) 1 (0.6) 3 (
In 1 patient after target lesion revascularization.
Abbreviations as in Table 1.igns. Such events are as clinically relevant as those occur-
Cing before TLR, and special attention should be paid to
tent thromboses occurring after TLR (10). On the other
and, treatment of in-stent restenoses in BMS with brachy-
herapy or implantation of DES makes the interpretation of
he long-term outcome of the initial treatment of these
atients even more difficult.
ubgroup analyses. Subgroup analyses revealed a substan-
ial effect in favor of SES implantation in all demographic
ubgroups of patients with complex coronary artery lesions,
ncluding those with diabetes. Thus, no signs of limited
ong-term effects of SES implantation in patients with this
isease could be recorded, a finding that concurs with that
f Sabaté et al. (27). In addition, the same tendency of
reatment effect was found in all types of lesions.
tudy limitations. The investigators initiated the study
nd were thus restrained from using identically appearing
anufactured stents. In addition, we chose to inform the
atients of the stent type they were allocated to. Thus, we
ave to take inherent methodologic limitations into consid-
ration when interpreting the clinical oucomes. On the
ther hand, the primary end point of the original study was
ngiographic, and clinical end points were all adjudicated by
blinded clinical events committee. In addition, the study is
trengthened by the fact that the manufacturer of the stents
as not involved in any part of the process, including
reparation of the protocol or case record form, monitoring,
nterpretation of the study results, or elaboration of the
anuscript.
onclusions
irolimus-eluting stent implantation, compared with BMS,
mproves the clinical outcome of patients and can be used
afely in patients with a variety of complex lesions without
ny increase in delayed restenosis or excess rate of adverse
vents, including stent thrombosis, up to 3 years after stent
mplantation, although careful monitoring of some of the
vents is still necessary.
eprint requests and correspondence: Dr. Henning Kelbæk,
ardiac Catheterization Laboratory, Rigshospitalet, DK–2100
BMS (n  157)
) Definite (%) Probable (%) Possible (%)
3 (1.9) 0 0
3 (1.9)* 0 0
0 1 (0.6%) 0
6 (3.8) 1 (0.6%) 0ble (%
0
0
1.9)
1.9)openhagen Ø, Denmark. E-mail: henning.kelbaek@rh.regionh.dk.
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